AEON Biopharma
AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine
October 19, 2023 16:05 ET | AEON Biopharma
– ABP-450 doses of 150 units and 195 units showed treatment effect of 4.8 days and 5.0 days, respectively, in the mean change from baseline in monthly migraine days (MMD) at weeks 21-24 but did not...
New Online Resource Tool Available for Persons with Migraine Disease to Help Address Healthcare Challenges
January 07, 2019 05:00 ET | Patient Advocate Foundation
Hampton, VA, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Patient Advocate Foundation (PAF) is excited to announce the launch of its new interactive educational widget, Migraine Matters, that empowers those...